



# Fiorenza Santamaria

---

**Nationality:** Italian | **Email address:** [fiorenza.santamaria@uniroma1.it](mailto:fiorenza.santamaria@uniroma1.it) |

**Address:** Viale Regina Elena 324, Department of Experimental Medicine, 00161, Roma, Italy (Work)

## ● ABOUT ME

---

M.D., Medical Oncologist  
Ph.D. fellow in "Network Oncology and Precision Medicine" at Sapienza University of Rome, Department of Experimental Medicine.

My research focuses on evaluating the impact of drug-drug interactions in clinical practice and optimizing complex therapies by integrating genomic, molecular, and clinico-pathological phenotype data.

Strong expertise in the clinical management of gastrointestinal and genitourinary cancers, as well as in the care of the oncogeriatric population.

Participation in over fifteen national congresses as a speaker and twelve national congresses as a scientific coordinator in the past five years.

## ● WORK EXPERIENCE

---

2024/07/01 - CURRENT Roma, Italy  
**ONCOLOGIST VILLA DEL ROSARIO**

---

## ● EDUCATION AND TRAINING

---

2023/01/01 - CURRENT Rome, Italy  
**PHD FELLOW IN "NETWORK ONCOLOGY AND PRECISION MEDICINE"** Università degli Studi di Roma "La Sapienza", Facoltà di Medicina e Psicologia

---

2017/12/29 - 2023/01/19 Roma, Italy  
**DOCTOR IN SPECIALIST TRAINING IN MEDICAL ONCOLOGY** Università degli Studi di Roma "La Sapienza", Facoltà di Medicina e Psicologia

---

2015/11/01 - 2016/01/31 Roma, Italy  
**MEDICAL REGISTER IN ROME, POSITION NUMBER: OMCEO ROMA M62285** Università degli Studi di Roma "La Sapienza", Facoltà di Medicina e Psicologia

---

2009/10/01 - 2025/09/29 Roma, Italy  
**DEGREE IN MEDICINE AND SURGERY** Università degli Studi di Roma "La Sapienza", Facoltà di Medicina e Psicologia

---

## ● LANGUAGE SKILLS

---

Mother tongue(s): **ITALIAN**

Other language(s): **ENGLISH**

## ● DIGITAL SKILLS

---

Excellent command of Office package | Excellent command of statistical analysis software | Good command of the "R" software

## ● PUBLICATIONS

---

2023

[Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis](#)

---

Signorelli, C.; Chilelli, M.G.; et al. *Cancers* 2023, 15, 5758

2023

[Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.](#)

---

Signorelli C., Calegari M.A., et al. *Curr. Oncol.* 2023, 30, 5456–5469

2024

[Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis](#)

---

Michele Basso, Carlo Signorelli, Maria Alessandra Calegari, et al.

2024

[Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset](#)

---

M. M. Germani, G. Vetere, F. Santamaria, et al.

2024

[Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments](#)

---

Fiorenza Santamaria, Michela Roberto, et al.

2024

[Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data \(IPD\) Meta-Analysis.](#)

---

2024

[Survival Outcomes with Regorafenib and/or Trifluridine/ Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study](#)

---

Signorelli C., Calegari M.A., et al.

● **PROJECTS**

---

2023/11/08 – CURRENT

**Evaluation of drug-drug interactions in prostate cancer patients during abiraterone, enzalutamide, apalutamide or darolutamide therapy using drug-pin software. The “DDI-AID” study.**

---

The research project is an observational, retro-prospective, real-world, multicenter study.

It enrolls metastatic prostate cancer patients receiving ARTA (Androgen Receptor Targeted Agents) treatment and at least one concomitant non-oncological medication.

The primary aim of the study is to evaluate the potential correlation between worse clinical outcomes (in terms of toxicity and survival) and the presence of drug-drug interactions between oncological treatments and concomitant medications.

The project involves collaboration among oncologists, pharmacologists, biologists, and biostatisticians.

The innovative aspect of this study lies in the prospective and systematic investigation of pharmacological interactions in clinical practice, targeting a group of patients with the same diagnosis and treatment who are not included in the registrational study of the drug.

2023/09/04 – CURRENT

**Evaluation of clinical impact of drug-drug interactions in metastatic colorectal cancer patients during 5FU-based chemotherapy using Drug-PIN software: a pooled post-hoc analysis of TRIBE and TRIBE2 studies.**

---

● **HONOURS AND AWARDS**

---

2024/07/31

**Coordinator of PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA – Policlinico Umberto I, Roma**

---

Coordinator “PERCORSO MULTIDISCIPLINARE DIAGNOSTICO-TERAPEUTICO (PDTA) IN ONCOLOGIA GERIATRICA” (Agenas n. 535- 426203, 40 ECM, from 31/07/2024 to 16/12/2024, 2 h/week).

2024/07/30

**Member of Scientific Committee of Dip. Interuniversitario Internazionale di Scienze Oncologiche – Consorzio Universitario Humanitas**

---

2024/05/17

**Member of "Osservatorio regionale sull'impatto economico delle leggi regionali" – Regione Lazio**

---

2023/10/10

**Winner of type 1B financing among “Bando di Ateneo 2023 per avvio alla ricerca” – Università degli Studi di Roma La Sapienza**

---

Project “EVALUTATION OF CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS IN METASTATIC COLORECTAL CANCER PATIENTS DURING 5FU-BASED CHEMOTHERAPY USING DRUG-PIN SOFTWARE: A pooled post-hoc analysis of TRIBE and TRIBE2 studies” approved by S.A. 263/2023 on 10.10.2023.

2021/12/12

**GOOD CLINICAL PRACTICE (GCP) Certificate – Nida clinical trials Network**

---

2015/09/29

**2013-2015 Percorso di Eccellenza in translational medicine – La Sapienza Università di Roma**


---

Research project “Personalized Medicine in patients with Multiple Chemical Sensibility”.  
Tutor: prof. Guglielmo Bruno and prof. Maurizio Simmaco.  
University of Rome “La Sapienza”, Faculty Of Medicine and Psychology.

---

*Fiorenza Santamaria, in compliance with Articles 46 and 76 of D.P.R. n. 445/2000, declares to be fully aware that false statements are punishable under the Penal Code and related laws. She certifies that the information provided in this CV is truthful and commits to providing all supporting documents upon request. Fiorenza Santamaria authorizes the use of her personal data in accordance with Legislative Decree 196/2003 on the protection of personal information and its subsequent amendments.*

Rome , 2025/01/03



Fiorenza Santamaria